Loading clinical trials...
Loading clinical trials...
This is a randomized, double-blind, parallel group, placebo-controlled, dose optimized, phase 3 study to evaluate the safety and efficacy of PRC-063 in the treatment of ADHD in adults
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Purdue Pharma, Canada
NCT05842330 · ADHD
NCT07478458 · ADHD - Attention Deficit Disorder With Hyperactivity
NCT07465081 · ADD/ADHD
NCT06655610 · ADHD - Attention Deficit Disorder With Hyperactivity
NCT06810180 · Attention Deficit Hyperactivity Disorder (ADHD), Sleep, and more
Meridien Research Inc.
Bradenton, Florida
Meridien Research
Lakeland, Florida
Meridien Research Inc.
Maitland, Florida
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions